Cancer test developer Accustem seeks Nasdaq uplisting, $10M offering (OTCMKTS:ACUT)
2d illustrations and photos Oncology diagnostics developer Accustem Sciences (OTCQB:ACUT) has filed to uplist its shares to Nasdaq and raise a proposed $10M through a public offering. Accustem didn’t specify in its filing the number and price of the shares it plans to offer, but indicated in an attached filing fee schedule that it was … Read more